| 1. |
劉會, 梁田, 劉桐希, 等. 抗合成酶綜合征合并肺間質疾病的臨床及影像征象分析. 中華放射學雜志, 2017, 51(10): 750-755.
|
| 2. |
Fu H, Zheng Z, Zhang Z, et al. Prediction of progressive pulmonary fibrosis in patients with anti-synthetase syndrome-associated interstitial lung disease. Clin Rheumatol, 2023, 42(7): 1917-1929.
|
| 3. |
Bell PT, Beaton T, Terrill M, et al. Anti-synthetase syndrome associated interstitial lung disease after combination dual immune checkpoint inhibition. Respirol Case Rep, 2023, 11(4): e01115.
|
| 4. |
Marguerie C, Bunn CC, Beynon HL, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med, 1990, 77(282): 1019-1038.
|
| 5. |
Lilleker JB, Vencovsky J, Wang G, et al. The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis, 2018, 77(1): 30-39.
|
| 6. |
Costa AN, Kawano-Dourado L, Shinjo SK, et al. Environmental exposure in inflammatory myositis. Clin Rheumatol, 2014, 33(11): 1689-1690.
|
| 7. |
Opinc AH, Makowska JS. Antisynthetase syndrome - much more than just a myopathy. Semin Arthritis Rheum, 2021, 51(1): 72-83.
|
| 8. |
羅瀾, 邢曉燕, 肖云抒, 等. 抗合成酶綜合征合并心臟受累患者的臨床及免疫學特征. 北京大學學報(醫學版), 2021, 53(6): 1078-1082.
|
| 9. |
Gasparotto M, Gatto M, Saccon F, et al. Pulmonary involvement in antisynthetase syndrome. Curr Opin Rheumatol, 2019, 31(6): 603-610.
|
| 10. |
Marco J L, Collins B F. Clinical manifestations and treatment of antisynthetase syndrome. Best Pract Res Clin Rheumatol, 2020, 34(4): 101503.
|
| 11. |
Shi J, Li S, Yang H, et al. Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies. J Rheumatol, 2017, 44(7): 1051-1057.
|
| 12. |
李文, 李俊, 謝萬木, 等. 抗合成酶綜合征合并間質性肺病患者的臨床特征. 中華醫學雜志, 2020, 100(24): 1861-1865.
|
| 13. |
趙娜, 劉穎, 孫小鳳, 等. 不同抗氨酰tRNA合成酶抗體陽性的抗合成酶綜合征60例臨床和影像學相關特征分析. 中華風濕病學雜志, 2019, 23(5): 320-325.
|
| 14. |
Zhan X, Yan W, Wang Y, et al. Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China. BMC Pulm Med, 2021, 21(1): 57.
|
| 15. |
Wilfong EM, Young-Glazer JJ, Sohn BK, et al. Anti-tRNA synthetase syndrome interstitial lung disease: a single center experience. Respir Med, 2022, 191: 106432.
|
| 16. |
趙琪, 鄒如意, 田亞瓊, 等. 糖皮質激素和他克莫司治療抗合成酶綜合征相關間質性肺疾病的療效及安全性分析. 中國呼吸與危重監護雜志, 2023, 22(3): 176-181.
|
| 17. |
Xu L, Wang F, Luo F. Rituximab for the treatment of connective tissue disease-associated interstitial lung disease: a systematic review and meta-analysis. Front Pharmacol, 2022, 13: 1019915.
|
| 18. |
毛萌萌, 郭炳鵬, 韓茜. 利妥昔單抗在抗合成酶綜合征相關性間質性肺炎中的治療進展. 中華結核和呼吸雜志, 2019, 42(10): 776-779.
|
| 19. |
Mecoli CA, Christopher-Stine L. Management of interstitial lung disease in patients with myositis specific autoantibodies. Curr Rheumatol Rep, 2018, 20(5): 27.
|
| 20. |
Wu W, Collins BF, Gardner GC, et al. Antisynthetase syndrome-related interstitial lung disease (ASyS-ILD): longitudinal imaging findings. Eur Radiol, 2023, 33(7): 4746-4757.
|
| 21. |
Liu H, Xie S, Liang T, et al. Prognostic factors of interstitial lung disease progression at sequential HRCT in anti-synthetase syndrome. Eur Radiol, 2019, 29(10): 5349-5357.
|
| 22. |
Zhao N, Jiang W, Wu H, et al. Clinical features, prognostic factors, and survival of patients with antisynthetase syndrome and interstitial lung disease. Front Immunol, 2022, 13: 872615.
|
1/5
WeChat